Gilteritinib with chemotherapy for FLT3-ITD positive AML
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests if adding the targeted drug gilteritinib to standard chemotherapy improves outcomes for adults with a specific type of AML (FLT3-ITD+). It's for newly diagnosed patients who can tolerate intensive treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 60 years old.
- You have been newly diagnosed with a type of AML called FLT3-ITD positive.
- Your general health is good (ECOG score 0, 1, or 2).
- Your liver and kidney function tests are within certain limits.
- You are not pregnant or breastfeeding.
- You do not have active serious infections, other cancers, or certain heart/lung conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of drugs (gilteritinib plus a chemo regimen called FLAI) as the first treatment for adults with a specific type of acute myeloid leukemia (AML) that has a FLT3 mutation. The goal is to see if this combination helps destroy leukemia cells better and with acceptable side effects.
This trial tests a three-drug combination for people with acute myeloid leukemia (AML) that did not respond to or came back after previous treatment with azacitidine and venetoclax. The goal is to see if adding gilteritinib can help control the leukemia.
This Phase 1/2 trial tests a combination of medicines (ASTX727, venetoclax, and gilteritinib) for adults with FLT3-mutated acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS). It aims to see how well the treatment works and how safe it is for people whose disease has come back, is not responding, or (for some) is newly diagnosed.
This study looks at how well new AML medicines work in everyday medical practice, outside of clinical trials. If you are starting a newer AML drug like gilteritinib, an IDH inhibitor, oral azacytidine, or others, you may be able to join.
This trial compares standard chemotherapy with newer drug combinations (CPX-351 and gilteritinib) for children and young adults with acute myeloid leukemia (AML), a type of blood cancer. It aims to find which treatment works better and who might benefit from targeted therapy based on specific genetic changes (FLT3 mutations).
This trial tests two maintenance drugs (gilteritini and sorafenib) for people with FLT3-ITD positive AML after a stem cell transplant. It compares which drug better prevents relapse using a sensitive test for minimal residual disease (MRD).
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.